APRETUDE

CABOTEGRAVIR · ViiV Healthcare Company

Drug timelines are a Plus or Pro feature.

26 regulatory and trial events tracked for APRETUDE, covering 2021-12-20 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)